1.Isolation of Subgroup J Avian Leukosis Virus in Korea.
Haan Woo SUNG ; Jae Hong KIM ; Sanjay REDDY ; Aly FADLY
Journal of Veterinary Science 2002;3(2):71-74
Two subgroup J avian leukosis viurses (ALVs) were isolated from broiler breeder flocks, in which myeloid leukosis had occurred. The isolates could be classified as subgroup J ALV. by the positive reaction in polymerase chain reaction (PCR) with primers specific for subgroup J ALV. Two isolates replicated in chicken embryo fibroblast (CEF) cells from the alv6 chicken line in which cells are resistant to subgroup A and E ALVs. In in vitro serum neutralization tests with other subgroup ALVs including ADOL-Hc1, the prototype of subgroup J ALVs isolated in the United States of America, two isolates were partially neutralized by antibody to ADOL-Hc1, indicating that Korean isolates and ADOL-Hc1 may be antigenically related, but not identical. When the PCR was done with a primer pair designed to amplify genes of E element and long terminal repeat of proviral DNA, the PCR product size of one isolate (KOAL-PET) was smaller than that of ADOL-Hc1, suggesting that some sequences in these regions are deleted.
Animals
;
Antibodies, Viral/immunology
;
Antigens, Viral/immunology
;
Avian Leukosis/virology
;
Avian leukosis virus/*classification/genetics/immunology/*isolation & purification
;
Cell Line
;
Chick Embryo
;
Chickens/*virology
;
Korea
;
Neutralization Tests
;
Polymerase Chain Reaction
;
Poultry Diseases/virology
2.Adjunctive acupuncture for pain and symptom management in the inpatient setting: protocol for a pilot hybrid effectiveness-implementation study.
Maria T CHAO ; Alexandra CHANG ; Sanjay REDDY ; James D HARRISON ; Joseph ACQUAH ; Miria TOVEG ; Trilce SANTANA ; Frederick M HECHT
Journal of Integrative Medicine 2016;14(3):228-238
BACKGROUNDEffective pain management among hospitalized patients is an important aspect of providing quality care and achieving optimal clinical outcomes and patient satisfaction. Common pharmacologic approaches for pain, though effective, have serious side effects and are not appropriate for all inpatients. Findings from randomized controlled trials (RCTs) support the efficacy of acupuncture for many symptoms relevant to inpatients including postoperative pain, cancer-related pain, nausea and vomiting, and withdrawal from narcotic use. However, the extent to which findings from RCTs translate to real-world implementation of acupuncture in typical hospital settings is unknown.
METHODS/DESIGNIn partnership with the launch of a clinical program offering acupuncture services to inpatients at the University of California San Francisco's Mount Zion Hospital, we are conducting a pilot study using a hybrid effectiveness-implementation design to: (1) assess the effectiveness of acupuncture to manage pain and other symptoms and improve patient satisfaction; and (2) evaluate the barriers and facilitators to implementing an on-going acupuncture service for inpatients. During a two-month pre-randomization phase, we evaluated and adapted clinical scheduling and treatment protocols with acupuncturists and hospital providers and pretested study procedures including enrollment, consent, and data collection. During a six-month randomization phase, we used a two-tiered consent process in which inpatients were first consented into a study of symptom management, randomized to be offered acupuncture, and consented for acupuncture if they accepted. We are also conducting in-depth interviews and focus groups to assess evidence, context, and facilitators of key provider and hospital administration stakeholders.
DISCUSSIONEffectiveness research in "real-world" practice settings is needed to inform clinical decision-making and guide implementation of evidence-based acupuncture practices. To successfully provide clinical acupuncture services and maintain a rigorous research design, practice-based trials of acupuncture require careful planning and attention to setting-specific, contextual factors.
TRIAL REGISTRATIONThis trial has been registered in ClinicalTrials.gov. The identifier is NCT01988194, registered on November 5, 2013.
Acupuncture Therapy ; Clinical Protocols ; Humans ; Inpatients ; Pain Management ; Pilot Projects